Blue Ledge Capital — Full Portfolio
9 tracked investments · listed companies and verified rows first
The American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities.
Digital HealthHealthtechImpact & Social Good
Co-investorsBrightEdgeFred Hutchinson Cancer Research Center
Grolltex manufactures single-layer graphene and graphene-based products using patented CVD and transfer technologies, serving customers in life sciences, biotech, sensing, and electronics.
BiotechDeep TechHardwareNew MaterialsSan Diego, US
Aliaksandr Victorovich Zaretski(Founder)in
Co-investorsVertical Venture PartnersTech Coast Angels
AvantGuard develops Avantamine, an antimicrobial molecule that eliminates bacteria, viruses, and fungi on surfaces and skin without generating resistance, with an initial focus on topical treatment of the drug-resistant fungal pathogen Candida auris.
BiotechHealthtechNew Materials
Co-investorsRed Bear AngelsSOSV
Mission Barns produces cultivated meat products, primarily pork-based items like meatballs, bacon, and sausages, combining lab-grown pork fat with plant protein for consumers seeking sustainable alternatives to conventional meat.
Climate TechFoodTechBerkeley, US
Ilan Eitan Fischer(Executive Officer, Director)
BoardDavid Bowman(Director)
Co-investorsAir Street CapitalBabel VenturesBetter Ventures Central LlcBloom8Joyance PartnersLever VC+6 more
Qnovia develops a portable, pre-filled vibrating mesh nebulizer (RespiRx) that delivers nicotine via ultrasonic nebulization without combustion, paired with a cloud-connected AI platform (Neblit) providing real-time behavioral support for smoking cessation.
AI & Machine LearningBiotechDigital HealthMedical DevicesRichmond, US
Mario Danek(Founder)inBrian Quigley(Executive Officer, Director)
BoardSean Fahey(Director)Brian Riano(Director)Gregg Smith(Director)in
Co-investorsEvolution VC PartnersVice Ventures
Developer of an inhalation device and liquid formulation to deliver inhalable nicotine without harmful constituents, pursuing FDA 505(b)(2) authorization for the first inhalable Nicotine Replacement Therapy; BlueLedge led its bridge rounds ahead of its 2020/2021 Series A.
Co-investorsEvolution VC PartnersSand Hill Angels
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.